Higher Efficiency of 131I-Labeled Anti-Carcinoembryonic Antigen—Monoclonal Antibody F(ab′)2 as Compared to Intact Antibodies in Radioimmunotherapy of Established Human Colon Carcinoma Grafted in Nude Mice

Radioimmunotherapy using 131I-labeled antibodies has been shown to be very efficient in patients with B cell lymphoma: 85% of patients responded with complete remission upon myeloablative therapy using radiolabeled MB-1 and B1 antibody (Press et al. 1993). In treatment of solid tumors, however, such response rates have not been reached (Mach et al. 1991; Goldenberg and Schlom 1993; Breitz et al. 1992).